Yajing Yang

发表

Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).

K. Rex, Matthew R. Lee, C. Dominguez, 2008, Journal of Medicinal Chemistry.

Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.

D. Whittington, Matthew R. Lee, C. Dominguez, 2012, Journal of medicinal chemistry.

Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.

K. Rex, K. Shah, Douglas Hoffman, 2008, Journal of medicinal chemistry.

Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.

K. Rex, K. Shah, S. Bellon, 2009, Bioorganic & medicinal chemistry letters.

Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors.

Kristin L. Andrews, B. Herberich, Matthew R. Lee, 2016, Bioorganic & medicinal chemistry letters.

AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

E. Lobenhofer, M. Friedrich, T. Raum, 2020, Clinical Cancer Research.

Sarcopenia Was a Poor Prognostic Predictor for Patients With Advanced Lung Cancer Treated With Immune Checkpoint Inhibitors

Jian-hua Chang, Yajing Yang, Zhou Liu, 2022, Frontiers in Nutrition.

Mitophagy—A New Target of Bone Disease

H. Cao, Yajing Yang, Ping Wang, 2022, Biomolecules.

Molecular Mechanism of Ferroptosis in Orthopedic Diseases

Yajing Yang, Guoxin Ni, Xuchang Zhou, 2022, Cells.

Design, synthesis, and biological evaluation of potent c-Met inhibitors.

Yuan Cheng, K. Rex, A. Coxon, 2008, Journal of medicinal chemistry.

c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations*

K. Rex, A. Coxon, A. Tasker, 2008, Journal of Biological Chemistry.

In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models

K. Rex, A. Coxon, M. Damore, 2016, Molecular Cancer Therapeutics.

Small-molecule Kinase Inhibitor with Antitumor Activity Identification of a Novel Recepteur D'origine Nantais/c-met Material Supplementary Cited Articles Citing Articles E-mail Alerts Identification of a Novel Recepteur D'origine Nantais/c-met Small-molecule Kinase Inhibitor with Antitumor Activity

K. Rex, A. Coxon, T. Burgess, 2022 .

Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.

K. Rex, A. Coxon, T. Burgess, 2008, Cancer research.

D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1

Q. Lei, Lei Lv, Yajing Yang, 2022, Proceedings of the National Academy of Sciences.

Abstract 6218: Discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor

A. Coxon, J. Canon, Kexue Li, 2020 .

Abstract 728: AMG 337, a novel, potent and selective MET kinase inhibitor, has robust growth inhibitory activity in MET-dependent cancer models

K. Rex, A. Coxon, R. Radinsky, 2014 .

Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.

K. Rex, D. Whittington, S. Bellon, 2012, Bioorganic & Medicinal Chemistry Letters.

ALDH1A1 promotes PARP inhibitor resistance by enhancing retinoic acid receptor-mediated DNA polymerase θ expression

Peixuan Guo, Qi-En Wang, Junran Zhang, 2023, NPJ precision oncology.

TET2 suppresses VHL deficiency-driven clear cell renal cell carcinoma by inhibiting HIF signaling.

Ruonan Zhang, Q. Lei, Yajing Yang, 2022, Cancer research.

TET2 is required to suppress mTORC1 signaling through urea cycle with therapeutic potential

Q. Lei, Ming Xu, Yajing Yang, 2023, Cell discovery.

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma

S. Psutka, M. Yin, Yajing Yang, 2023, Frontiers in oncology.

Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.

K. Rex, K. Shah, S. Bellon, 2009, Bioorganic & medicinal chemistry letters.